HOME >> MEDICINE >> NEWS
European trial finds old lung cancer treatment may still be best

The first clinical trial to compare directly two of the most widely-used drugs in advanced lung cancer, cisplatinin and carboplatin (both in combination with paclitaxel) have concluded that the older drug, cisplatin, is the better treatment.

Patients given cisplatin and paclitaxel had better survival rates and their quality of life was just as good as patients receiving carboplatin and paclitaxel.

The phase III multi-national European trial involving 618 patients with advanced non small-cell lung cancer (NSCLC) is reported in the new issue of Annals of Oncology.*

Cisplatin tends to be the preferred standard chemotherapy for lung cancer in Europe, but in the USA carboplatin is normally used. The new findings are in contrast to a recent similar study in the USA** where a four-arm trial comparing a range of treatments showed no advantage for any one chemotherapy combination over another.

In the European trial the response rates to the two treatments were similar - 28% in the cisplatin/paclitaxel arm and 25% in the carboplatin/paclitaxel arm, but the median survival in the cisplatin arm was significantly better at 9.8 months compared with 8.5 months. The one-year survival rate was 38% in the cisplatin/paclitaxel arm compared with 33% in the carboplatin/paclitaxel arm and the two-year survival rate was 15% and 9% respectively.

Lead investigator Dr Rafael Rosell from the Hospital Germans Trias i Pujol in Barcelona, Spain said: "This large European randomised study can contribute greatly to resolving the longstanding debate on the superiority of carboplatin or cisplatin-based chemotherapy in lung cancer. Although paclitaxel/carboplatin yielded a similar response rate, the significantly longer median survival obtained with paclitaxel/cisplatin indicates that cisplatin-based chemotherapy should be the first treatment option." However, Dr Rosell stressed that paclitaxel/carboplatin was still a viable alternative.

In an acco
'"/>

Contact: Margaret Willson
m.willson@mwcommunications.org.uk
44-153-677-2181
European Society for Medical Oncology
9-Oct-2002


Page: 1 2

Related medicine news :

1. ESC releases the first European Guidelines on Percutaneous Coronary Interventions (PCI)
2. The European Society of Cardiology launches Women at Heart
3. Use of potentially inappropriate medications among elderly common in some European countries
4. European folic acid policies are not effective enough
5. New European cancer figures for 2004 major efforts needed against the big four killers
6. Third of European cancer patients use complementary and alternative therapies
7. A new service from the European Patent Office
8. European study highlights persistent 3 decade increase in childhood cancer incidence
9. European nations urged to ratify international treaty on tobacco control
10. Increased investment in radiotherapy will improve cure rates for European cancer patients
11. ESA looking for more European women to volunteer for WISE bed-rest study in Toulouse next year

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: European trial finds old lung cancer treatment may still best

(Date:10/25/2014)... CA (PRWEB) October 25, 2014 ... biology, today announced Dr. Xun Wang ... all Research & Development. , Triton has developed a ... value algae-based proteins. According to Dr. Wang, the platform ... traditional expression systems. He says, “Algae are unique because ...
(Date:10/25/2014)... (PRWEB) October 25, 2014 The global ... CAGR of 7.6%, to reach $50.4 billion by 2018 ... healthcare systems industry, and pharmaceutical industry are driving the ... model to enhance their focus on core business, reduce ... and trained staff (further reducing hiring and training costs), ...
(Date:10/25/2014)... Background: , In 1998 Bob Savage founded the Connecticut ... the field of establishing recovery community organizations. Bob had ... he retired, he set out to answer a couple questions ... , 1. Where are the people in recovery when ... Can the recovery community be organized to advocate for issues ...
(Date:10/25/2014)... 2014 Market Research Report ... 2009-2019 is a professional and in-depth market ... industry. The report firstly reviews the basic ... application and manufacturing technology. The report then ... Molecular Diagnostics listing their product specification, capacity, ...
(Date:10/25/2014)... York (PRWEB) October 25, 2014 ... lawsuits ( http://www.vaginalmeshlawsuit2015.com/ ) filed against Boston ... in U.S. District Court, Southern District of West ... Judgment on Punitive Damages in a group of ... a ruling issued on October 21st, U.S. District ...
Breaking Medicine News(10 mins):Health News:Triton Algae Innovations Ltd. Names Dr. Xun Wang as President 2Health News:Triton Algae Innovations Ltd. Names Dr. Xun Wang as President 3Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 2Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 3Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 4Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4
(Date:10/25/2014)...  In 2008, two of Dr. Gurney,s employees reported ... substances, on a regular basis, that were not used ... was practicing "all the time" while under the influence. ... said that Dr. Gurney was prone to "making mistakes ... Dr. Gurney,s behavior became increasingly erratic and unfocused, and ...
(Date:10/25/2014)... , Oct. 24, 2014 In conjunction ... quarter 2014 financial results press release, you are invited ... broadcast live over the internet on Monday, November 3, ... Time). A live audio webcast of the ... http://www.durect.com and clicking "Investor Relations."  If you ...
(Date:10/25/2014)... , Oct. 24, 2014 Burzynski Research Institute, ... Drug Administration (FDA) has given the company permission to ... in patients > 3 months of age with a ... placed in one of five treatment groups based on ... prior treatment for DIPG. The primary study endpoint is ...
Breaking Medicine Technology:Doctors That Harm: The Real Stories Insurance Companies Against Prop 46 Don't Want You To Know, Part 8 of Consumer Watchdog Campaign Series 2Doctors That Harm: The Real Stories Insurance Companies Against Prop 46 Don't Want You To Know, Part 8 of Consumer Watchdog Campaign Series 3DURECT Corporation Invites You to Join its Third Quarter 2014 Earnings Conference Call 2Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2
Cached News: